| Title |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
|
|---|---|
| Published in |
BMC Cancer, April 2009
|
| DOI | 10.1186/1471-2407-9-112 |
| Pubmed ID | |
| Authors |
Jean-Luc Raoul, Jean-Luc Van Laethem, Marc Peeters, Catherine Brezault, Fares Husseini, Laurent Cals, Johannes Nippgen, Anja-Helena Loos, Philippe Rougier |
| Abstract |
This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Germany | 1 | 3% |
| Unknown | 31 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 24% |
| Other | 7 | 21% |
| Student > Master | 4 | 12% |
| Student > Bachelor | 3 | 9% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 4 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 48% |
| Agricultural and Biological Sciences | 5 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Nursing and Health Professions | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 5 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2014.
All research outputs
#15,302,478
of 22,758,248 outputs
Outputs from BMC Cancer
#4,106
of 8,277 outputs
Outputs of similar age
#79,157
of 93,785 outputs
Outputs of similar age from BMC Cancer
#25
of 29 outputs
Altmetric has tracked 22,758,248 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,277 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,785 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.